- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04087369
Integrated NCD Intervention in Rural Nepal
An Integrated Intervention for Chronic Care Management in Rural Nepal: a Type 2 Hybrid Effectiveness-implementation Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Achham/Province 7
-
Sanfebagar-10, Achham/Province 7, Nepal
- Bayalpata Hospital
-
-
Dolakha/Province 3
-
Charikot, Dolakha/Province 3, Nepal
- Charikot Primary Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged 18 or older that screen into Nyaya Health Nepal/Possible's chronic disease program for the following conditions: Hypertension, Type II Diabetes Mellitus, COPD, and Asthma OR
- Adult patients aged 18 or older with end-organ pathology resulting from the aforementioned conditions including the following: Chronic Kidney Disease, Ischemic Heart Disease, Cerebrovascular Disease AND
Healthcare staff; mid-level providers serving at district/primary health center-level facility; community health workers serving village clusters, Nyaya Health Nepal/Possible and Government of Nepal/Ministry of Health and Population employees involved in study design, program implementation, data collection, or data analysis processes.
Note, study populations 1 and 2 must reside in either Achham or Dolakha (Nepal) districts.
Patients must have a noncommunicable note in electronic medical record system at least twice (indicating at least one follow-up visit) and must have minimum 12 weeks in between baseline/endline clinical measures (indicating patients have been followed up for at least 3 months and have 3 months of exposure to intervention).
- Patients do not need to have been in study for all 3 years. Duration of exposure to intervention will depend on stepped implementation design.
Patients may be identified at Bayalpata Hospital (Achham, Nepal) or Charikot Primary Health Center (Dolakha, Nepal) by facility clinicians. Community health workers can also identify hypertensive patients and refer them to the facility for diagnosis confirmation. Patient enrollment will not be restricted by economic status or caste. Patients will not be recruited exclusively to participate in the study but will undergo routine evaluations, entering the final diagnosis in electronic health record system, tracking progress at each patient contact, the frequency for which is determined by the clinician's recommendation per World Health Organization Package of Essential Noncommunicable disease intervention protocols and the patient's availability. Patients will receive longitudinal care via the community health workers at their homes and at the hospitals by mid-level providers and staff physicians. Their receipt of care is not contingent upon their enrollment in the study; they receive care per routine service delivery.
Exclusion Criteria:
- Patients migrate from the study are before completion of any of the Package of Essential Noncommunicable disease interventions
- Patients explicitly request exclusion from the study and decline to consent to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Bundled NCD WHO PEN Intervention
Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
|
In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population.
In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Type II diabetes mellitus control measure
Time Frame: 24 months
|
Percentage of enrolled type II diabetes patients achieving "at goal" status, at the completion of the study period (type II diabetes mellitus: Hemoglobin A1c < 7.5 OR fasting blood sugar <130 mg/dL)
|
24 months
|
|
Hypertension control measure
Time Frame: 24 months
|
Percentage of enrolled hypertension patients achieving "at goal" status, at the completion of the study period (hypertension: blood pressure <130/80mm Hg or patient-tailored goal per risk stratification)
|
24 months
|
|
COPD control measure
Time Frame: 24 months
|
Percentage of enrolled COPD patients achieving "at goal" status, at the completion of the study period (COPD: exacerbation status ≤1/3 Anthonisen criteria)
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tobacco use
Time Frame: 24 months
|
Percentage of enrolled NCD patients who were using tobacco at enrollment who are non-users or who have reduced by >50% their tobacco intake, at the completion of the study period
|
24 months
|
|
Alcohol use
Time Frame: 24 months
|
Percentage of enrolled NCD patients who were alcohol drinkers at enrollment who are non-drinkers or who have reduced by >50% alcohol intake, at the completion of the study period
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Home visit coverage (Reach)
Time Frame: 1 month
|
Percentage of enrolled NCD patients having a CHW home visit
|
1 month
|
|
Clinic visit coverage (Reach)
Time Frame: 1 month
|
Percentage of enrolled NCD patients having an MLP visit at the clinic, measured monthly according to the patients indicated to be seen that month based on protocol-based guidelines
|
1 month
|
|
Demographic, geographic barriers and facilitators
Time Frame: 24 months
|
Percentage of enrolled NCD patients whose CHW has GPS-mapped their households, describing barriers/facilitators to individuals' access, and identifying contributors to variation/inequities
|
24 months
|
|
Loss to follow-up (Reach)
Time Frame: 24 months
|
Percentage of patients, stratified by demographic data and NCD conditions, that are lost-to-follow-up after enrollment
|
24 months
|
|
Monthly patient touch-points (Effectiveness)
Time Frame: 1 month
|
Number of monthly per-patient touch-points, including interactions by both MLPs and CHWs
|
1 month
|
|
Evidence-based hypertension management (Effectiveness)
Time Frame: 3 months
|
Percentage of enrolled hypertension patients in accordance with evidence-based recommendations, as prescribed by clinical algorithms, assessed quarterly by EHR audits
|
3 months
|
|
Evidence-based diabetes management (Effectiveness)
Time Frame: 3 months
|
Percentage of enrolled diabetes patients in accordance with evidence-based recommendations, as prescribed by clinical algorithms, assessed quarterly by EHR audits
|
3 months
|
|
Evidence-based COPD management (Effectiveness)
Time Frame: 3 months
|
Percentage of enrolled COPD patients in accordance with evidence-based recommendations, as prescribed by clinical algorithms, assessed quarterly by EHR audits
|
3 months
|
|
Village cluster adoption (Adoption)
Time Frame: 24 months
|
Percentage of intended village clusters receiving intervention
|
24 months
|
|
Timely adoption (Adoption)
Time Frame: 24 months
|
Percentage of intended village clusters rolling-out intervention within 3 months of schedule, according to local governance decisions to roll-out the intervention
|
24 months
|
|
CHW training adoption (Adoption)
Time Frame: 6 months
|
Percentage of CHWs trained in intervention implementation within first six months
|
6 months
|
|
CHW retention adoption (Adoption)
Time Frame: 24 months
|
Percentage of of trained CHWs retained in their positions at the completion of the study period
|
24 months
|
|
MLP training adoption (Adoption)
Time Frame: 24 months
|
Percentage of MLPs trained in intervention implementation
|
24 months
|
|
MLP retention adoption (Adoption)
Time Frame: 24 months
|
Percentage of of trained MLPs retained in their positions at the completion of the study period
|
24 months
|
|
Care integration (Implementation)
Time Frame: 1 month
|
Percentage of all NCD patients enrolled at the facilities seen by CHWs at home within first month
|
1 month
|
|
CHW supervision completion (Implementation)
Time Frame: 3 months
|
Percentage of scheduled CHW supervision field visits completed, stratified by CHN and district
|
3 months
|
|
CHW supervision review meeting completion (Implementation)
Time Frame: 3 months
|
Percentage of scheduled quarterly data review meetings held with CHWs and CHNs
|
3 months
|
|
CHW home visit completion (Implementation)
Time Frame: 3 months
|
Percentage of enrolled NCD patients with 100% of algorithm-indicated home visits received
|
3 months
|
|
CHW home visit fidelity (Implementation)
Time Frame: 3 months
|
Percentage of of topics included at each session as dictated by the condition-specific algorithms, assessed during the CHW supervision field visits by CHNs
|
3 months
|
|
Referral fidelity (Implementation)
Time Frame: 3 months
|
Percentage of patients appropriately referred to MLP care as indicated by the clinical algorithms, assessed during the CHW supervision field visits by CHNs
|
3 months
|
|
Referral completion (Implementation)
Time Frame: 3 months
|
Percentage of % of patients referred by CHWs seen by MLPs within the prescribed time window according to the clinical algorithms (e.g.
24hours, 72 hours, 1 week)
|
3 months
|
|
MLP supervision model (Implementation)
Time Frame: 3 months
|
Percentage of enrolled NCD patients appropriately referred to see a physician by MLPs as indicated by the clinical algorithms, assessed during monthly physician supervision sessions
|
3 months
|
|
MLP visit fidelity (Implementation)
Time Frame: 1 month
|
Percentage of of enrolled NCD patients with 100% of algorithm-indicated facility visits received, assessed during monthly physician supervision sessions
|
1 month
|
|
Total intervention cost (Maintenance)
Time Frame: 24 months
|
Cost of each intervention component and total costs using the Joint Learning Network costing methodology
|
24 months
|
|
Intervention initiation costs (Maintenance)
Time Frame: 24 months
|
Percentage breakdown of initial (one-time) costs for intervention (training, equipment, etc)
|
24 months
|
|
Intervention maintenance costs (Maintenance)
Time Frame: 24 months
|
Percentage breakdown of maintenance (recurring) costs (on-going training, personnel, materials, and other)
|
24 months
|
|
Facility vs. community costs (Maintenance)
Time Frame: 24 months
|
Percentage of costs of health care divided between facility level and community level
|
24 months
|
|
Geographic cost variation (Maintenance)
Time Frame: 24 months
|
Variance in costs between village clusters and districts within the intervention catchment area
|
24 months
|
|
Out-of-pocket patient costs (Maintenance)
Time Frame: 24 months
|
Percentage of costs of health care divided between facility level and community level
|
24 months
|
|
Integrated intervention cost-effectiveness analysis (Maintenance)
Time Frame: 24 months
|
Pre/post intervention marginal effectiveness for primary outcomes
|
24 months
|
|
Cost per unit patient (Maintenance)
Time Frame: 24 months
|
Intervention cost per enrolled patient
|
24 months
|
|
Cost per capita (Maintenance)
Time Frame: 24 months
|
Intervention cost per capita
|
24 months
|
|
Projected scale cost(Maintenance)
Time Frame: 24 months
|
Projected cost to scale intervention nationally
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sabitri Sapkota, PhD, MPH, Possible/Nyaya Health Nepal
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCDnyaya
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on Bundled NCD WHO PEN Intervention
-
PossibleNational Institute of Mental Health (NIMH); Brigham and Women's Hospital; University... and other collaboratorsUnknown
-
Yale UniversityNot yet recruiting
-
Aga Khan UniversityRoyal Society of Tropical Medicine and Hygiene (RSTMH) funded by NIHRNot yet recruitingCardiovascular Diseases | Lung Diseases | Diabetes Mellitus | Cancer
-
Jackson State UniversityHarvard School of Public Health (HSPH); University of Mississippi Medical Center and other collaboratorsRecruitingMaternal Behavior | Postpartum Mood DisturbanceUnited States
-
Jackson State UniversityHarvard School of Public Health (HSPH); University of Mississippi Medical Center and other collaboratorsRecruitingContraception | Maternal Behavior | Health Literacy | Family Dynamics | Postpartum Mood Disturbance | Trust in Healthcare System | Family StructureUnited States
-
University Hospital, BonnGerman Federal Ministry of Education and ResearchUnknown
-
University of Alaska AnchorageNational Institute of General Medical Sciences (NIGMS)CompletedDepression | Anxiety | Suicidal Ideation | Substance UseUnited States
-
Khyber Teaching HospitalNot yet recruitingLabor and DeliveryPakistan
-
Mouetaz KheirallahActive, not recruiting
-
St. Jude Children's Research HospitalNot yet recruitingSubstance Use | Survivors of Childhood CancerUnited States